Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3901032 | 1.00 | BTK (0.55) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL6510047 | 1.00 | BTK (0.55) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL16295450 | 1.00 | BTK (0.55) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL19156343 | 1.00 | BTK (0.55) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL3903151 | 1.00 | BTK (0.55) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL1155174 | 1.00 | BTK (0.55) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL25319683 | 0.91 | BTK (0.64) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL941984 | 0.91 | BTK (0.64) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL2377443 | 0.91 | BTK (0.64) | BTKDRD2NR1H2KDM1AMAOB | |
| SCHEMBL21027650 | 0.91 | BTK (0.64) | BTKDRD2NR1H2KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | claimed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2025045777-A1 | INHIBITORS OF PCSK9 | DRAUPNIR BIO APS (DK) | 2025-03-06 | — | — | WO | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022165529-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| CN-113840597-A | Integrated stress response pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-109689661-B | Macrocyclic inhibitors of myeloperoxidase | 百时美施贵宝公司 | 2021-10-15 | — | — | CN | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACETUCALS, S.A. | 2006-06-29 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
| WO-2005075426-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-08-18 | — | — | WO | disclosed |
| EP-0644872-B1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS | CIBA GEIGY AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| US-5516806-A | ANTITUMOR | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0644872-A1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS. | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994024093-A1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | DPP4, DPP3, DPP7 | BTK 3741/4885DRD2 2892/4885NR1H2 3424/4885 |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | BTK 676/4885DRD2 4720/4885NR1H2 1926/4885 |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | BTK 2230/4885DRD2 54/4885NR1H2 386/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | BTK 1242/4885DRD2 2592/4885NR1H2 2769/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | BTK 1242/4885DRD2 2592/4885NR1H2 2769/4885 |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | BTK 3888/4885DRD2 3398/4885NR1H2 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.